|Dr. Maurice Zauderer||Co-Founder, CEO, Pres & Director||336.77k||N/A||1945|
|Mr. Raymond E. Watkins||Sr. VP & COO||235.37k||N/A||1958|
|Dr. Ernest S. Smith||Sr. VP of Research & Chief Scientific Officer||235.48k||N/A||1972|
|Dr. Deepak M. Sahasrabudhe||Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical Advisor||N/A||N/A||N/A|
|Mr. Scott E. Royer C.F.A., M.B.A.||Chief Financial Officer||N/A||N/A||1974|
Vaccinex, Inc., a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and potentially for other autoimmune disorders; VX25, a bi-specific natural killer T (NKT) cell stimulator, for the therapeutic application of NKT cell stimulation for cancer immunotherapy; BVX20, an investigational and humanized monoclonal antibody for the treatment of for multiple sclerosis. It has a clinical trial collaboration and supply agreement with Merck KGaA to test pepinemab in combination with avelumab checkpoint inhibitor in NSCLC patients. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.
Vaccinex, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.